These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10472407)

  • 1. [Severe constriction of the visual field associated with vigabatrin discovered by thorough examination of a 17-year old girl].
    Roubergue A; Pelosse B; Doummar D; Beauvais P; Montchilova M; Gonthier B; Billette de Villemeur T
    Arch Pediatr; 1999 Aug; 6(8):901-2. PubMed ID: 10472407
    [No Abstract]   [Full Text] [Related]  

  • 2. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin.
    Ruether K; Pung T; Kellner U; Schmitz B; Hartmann C; Seeliger M
    Arch Ophthalmol; 1998 Jun; 116(6):817-9. PubMed ID: 9639460
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversibility of vigabratin-induced visual-field defect.
    Versino M; Veggiotti P
    Lancet; 1999 Aug; 354(9177):486. PubMed ID: 10465180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin.
    Mackenzie R; Klistorner A
    BMJ; 1998 Jan; 316(7126):233. PubMed ID: 9468717
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing.
    Blackwell N; Hayllar J; Kelly G
    BMJ; 1997 Jun; 314(7095):1694. PubMed ID: 9193313
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe persistent visual field constriction associated with vigabatrin.
    Eke T; Talbot JF; Lawden MC
    BMJ; 1997 Jan; 314(7075):180-1. PubMed ID: 9022432
    [No Abstract]   [Full Text] [Related]  

  • 7. Severe persistent visual field constriction associated with vigabatrin. Benefit: risk ratio must be calculated for individual patients.
    Harding GF
    BMJ; 1998 Jan; 316(7126):232-3. PubMed ID: 9468716
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist.
    Harding GF
    BMJ; 1997 Jun; 314(7095):1694. PubMed ID: 9193314
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe persistent visual field constriction associated with vigabatrin. Manufacturers have started several studies.
    Backstrom JT; Hinkle RL; Flicker MR
    BMJ; 1997 Jun; 314(7095):1694-5. PubMed ID: 9193315
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent.
    Wong IC; Mawer GE; Sander JW
    BMJ; 1997 Jun; 314(7095):1693-4. PubMed ID: 9193312
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions.
    Wilson EA; Brodie MJ
    BMJ; 1997 Jun; 314(7095):1693. PubMed ID: 9193311
    [No Abstract]   [Full Text] [Related]  

  • 12. Infantile spasms and vigabatrin. Visual field defects may be permanent.
    Lhatoo SD; Sander JW
    BMJ; 1999 Jan; 318(7175):57. PubMed ID: 10068225
    [No Abstract]   [Full Text] [Related]  

  • 13. Vigabatrin-associated retinal cone system dysfunction.
    Brigell MG
    Neurology; 1998 Dec; 51(6):1779-81. PubMed ID: 9855563
    [No Abstract]   [Full Text] [Related]  

  • 14. Vigabatrin-associated retinal cone system dysfunction.
    Roubertie A; Bellet H; Echenne B
    Neurology; 1998 Dec; 51(6):1779-81. PubMed ID: 9855564
    [No Abstract]   [Full Text] [Related]  

  • 15. Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favorable factor?
    Giordano L; Valseriati D; Vignoli A; Morescalchi F; Gandolfo E
    Neurol Sci; 2000 Jun; 21(3):185-6. PubMed ID: 11076009
    [No Abstract]   [Full Text] [Related]  

  • 16. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
    Sergott RC; Bittman RM; Christen EM; Sagar SM
    Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vigabatrin-associated retinal cone system dysfunction.
    Beck RW
    Neurology; 1998 Dec; 51(6):1778-9; author reply 1779-81. PubMed ID: 9855562
    [No Abstract]   [Full Text] [Related]  

  • 18. [Visual field defects due to antiepileptic drugs].
    Stefan H; Bernatik J; Knorr J
    Nervenarzt; 1999 Jun; 70(6):552-5. PubMed ID: 10412701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents.
    Baulac M; Nordmann JP; Lanoé Y
    Lancet; 1998 Aug; 352(9127):546. PubMed ID: 9716066
    [No Abstract]   [Full Text] [Related]  

  • 20. Symptomatic and asymptomatic visual loss in patients taking vigabatrin.
    Daneshvar H; Racette L; Coupland SG; Kertes PJ; Guberman A; Zackon D
    Ophthalmology; 1999 Sep; 106(9):1792-8. PubMed ID: 10485552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.